Marie O’Farrell - Concepedia

Author

Marie O’Farrell

Pacific Biosciences (United States)

Also Known As

M. O'Farrell, Marie O'Farrell, Marie O’Farrell, O’Farrell, M

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

Pacific Biosciences (United States)The University of Texas Health Science Center at San Antonio University of Manchester Sarah Cannon Research Institute Sarah Cannon

About

Marie O’Farrell is an author at Pacific Biosciences (United States) specializing in medicine, cell biology, and tumor microenvironment.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	249
2	Cell Biology	2	2	249
3	Health Sciences	1	1	89
4	Immunology	1	1	89
5	Metabolism	1	1	89

Marie O’Farrell

Publications

Citations

H-Index

Page 1

	Year	Citations
First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors Gerald S. Falchook, Jeffrey R. Infante, Hendrik‐Tobias Arkenau, EClinicalMedicine	2021	250
TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial Rohit Loomba, Rizwana Mohseni, Kathryn Jean Lucas, Gastroenterology	2021	204
p21-Activated Kinase 1 Is Required for Efficient Tumor Formation and Progression in a Ras-Mediated Skin Cancer Model Hoi Yee Chow, Adrian M. Jubb, Jennifer N. Koch, Cancer Research Tumor RegressionRas GenesDermatologyCancer BiologyTumor Biology	2012	160
Therapeutic efficacy of FASN inhibition in preclinical models of HCC Haichuan Wang, Yi Zhou, Hongwei Xu, Hepatology	2022	115
FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models Marie O’Farrell, G M Duke, R. Webster Crowley, Scientific Reports ImmunologyCell DeathFatty Liver DiseaseFatty Acid SynthaseInflammation	2022	89
Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial Rohit Loomba, Pierre Bédossa, Katharine Grimmer, The Lancet. Gastroenterology & hepatology	2024	72
Fatty acid synthesis suppresses dietary polyunsaturated fatty acid use Anna Worthmann, Julius Ridder, Sharlaine Piel, Nature Communications	2024	48
Preliminary activity in the first in human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640. Emma Dean, Gerald S. Falchook, Manish R. Patel, Journal of Clinical Oncology	2016	43
Preclinical Characterization of PWT143, a Novel Selective and Potent Phosphatidylinositol 3-kinase Delta (PI3K delta) Inhibitor with Ex-Vivo Activity in Hematologic Malignancies. Marie O’Farrell, Richard Ventura, Albert Tai, Blood	2012	20
Pharmacological induction of membrane lipid poly-unsaturation sensitizes melanoma to ROS inducers and overcomes acquired resistance to targeted therapy Ali Talebi, Vincent de Laat, Xander Spotbeen, Journal of Experimental & Clinical Cancer Research	2023	16

Page 1